Drug Trial Radar · NCT04105543
CLR 131 Combined With Radiation for Head and Neck Cancer
Last checked: Nov 19, 2026Latest source record: Sep 2, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
12
Actual
Start
Dec 20, 2019
Primary completion
Sep 19, 2022
Study completion Feb 1, 2024
Sponsor
- Lead sponsor
- University of Wisconsin, MadisonAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- National Institute of Dental and Craniofacial Research (NIDCR); Cellectar Biosciences, Inc.
- First posted
- Sep 26, 2019
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a Phase 1 study of the use of an investigational drug that selectively delivers radiation to malignant tumor cells, CLR 131, in combination with external beam radiation therapy (EBRT) in subjects with locoregionally recurrent head and neck cancer. The trial will enroll up to 12 participants who are amenable to retreatment with radiation therapy. Participants who also have distant metastatic disease may be enrolled on this clinical trial, but they must have evaluable disease that will be clinically treated with radiation therapy, as per standard of care. All participants will receive a dosimetry test dose of CLR 131 to establish drug uptake by the tumor and enable Monte Carlo dose estimation based on CLR 131 SPECT/CT imaging evaluation. Participants showing uptake will receive a cumulative tumor dose of 60-70 Gy using personalized dose calculation (via Monte Carlo methods) of CLR 131 combined with external beam radiation.
Conditions
- Head and Neck Cancer
Interventions
CLR 131Drug
CLR 131 is a radiopharmaceutical dosed intravenously over a period of approximately 30 minutes, dose will be based on total body surface area calculated from actual body weight and height
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of Treatment Related Adverse EventsTime frame: up to 18 weeks
- Summary of Adverse Events Possibly Related to TreatmentTime frame: up to 18 weeks
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
UW Cancer Center Johnson Creek
Johnson Creek, Wisconsin
University of Wisconsin Carbone Cancer Center
Madison, Wisconsin
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.